🔗 Share this article

Given that the US continues making sweeping revisions to its vaccine guidelines, one figure has emerged in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by expressing skepticism about COVID-19 shots during the pandemic and has focused upon alleged deaths after Covid vaccination in her recent time at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Vaccine Schedule

Health officials had intended to announce major changes to the childhood immunization program in December, synchronizing the US with Denmark’s immunization schedule, it is understood – a substantial departure that would put the US out of step with many the world with little proof for improved outcomes. The planned update has been delayed until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this calendar year.

A New Direction at the Regulatory Body

The acting appointment might represent a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a greater focus upon rolling back long-standing vaccines at the FDA.

The new acting director has often pushed for discontinuing some childhood vaccine recommendations in the US so as to align more in line with the Danish model, a society with universal health coverage and a population about the population of Wisconsin’s.

In her initial comments, she has continued to focus on immunizations – usually the purview of Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Concerns Over Expertise

The appointee has little discernible experience in drug development, regulation or management, which has been standard for previous leaders of the biologics center. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“She appears not to have the necessary background” for running the CDER, stated a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in managing a major agency. She is not an expert in pharmaceutical oversight.”

Former commissioners of CBER would “grasp legal statutes and the underlying principles of medication creation”, said a former acting FDA commissioner. “Frankly, she lacks the type of experience that former directors who ran CBER have had.”

This division has an immense range of responsibilities at the FDA, the former commissioner stated.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office approves a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and other areas, and each of these must be looked after,” Woodcock said. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

Furthermore, a major leadership element to the position, which supervises more than 5,000 employees. “It’s a massive leadership role, if you do it right,” the former official said.

Official Statement and Controversial Programs

When asked about inquiries about Dr. Høeg's credentials and whether this assignment indicates greater collaboration among agency officials on vaccines, a spokesperson stated that the “inquiries stem from inaccurate presumptions”.

“This background matches the functions of her position,” the spokesperson said, noting the months Dr. Høeg spent advising the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s controversial priority voucher program, a contentious one-day drug-approval program that apparently concerned her former heads. “By what process are these drugs being chosen for this expedited pathway? Who makes the calls?” Dr. Howard questioned. “There is a lot of secrecy occurring at the FDA right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards laxer regulations of most medications, except for immunizations.”

Established History on Immunizations

With vaccines, Dr. Høeg has a more documented, if concerning, track record, some experts said. She published a analysis using unverified public submissions to estimate the incidence of myocarditis following COVID-19 vaccination. She counseled the Florida surgeon general Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are riskier than they are.

Included in her “desired changes” for the incoming federal leadership featured revising regulations for new vaccines and halting “non-essential” immunizations, she stated post-election on a audio program. At the FDA, Dr. Høeg has according to sources floated the idea of preventing adolescent males from getting Covid vaccinations.

“She’s an complete true believer who starts off with her beliefs and reverse-engineers to accommodate the data in a extremely disingenuous, fraudulent fashion,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Høeg aligned with other contrarians, {like|